ANIP News and Press, ANI Pharmaceuticals Inc. From 12/16/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following the initial devastation of the coronavirus pandemic, the U.S. economy has so far engineered an impressive recovery. Although not every metric is perfectly aligned, we can say this much: the early (and understandab...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

-- Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner -- -- Proven track record with largest number of Competitive Generic Therapy (CGT) approvals -- -- Deep pipeline wit...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as f...

The Federal Trade Commission has granted clearance for ANI Pharma's (NASDAQ:ANIP) acquisition of Novitium Pharmaceuticals. As a condition of the acquisition, the companies are divesting two generic products. ANI says that divestiture will have no impact on its business. ANI expects the merger...

-- Divestiture Required by FTC of Two Generic Products Immaterial to Company’s Business -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connect...

ANI Pharmaceuticals (ANIP -5.4%), which agreed to acquire Novitium Pharma for $163.5M, will need to divest two generic products as a condition of the merger, per an FTC order. Development rights to sulfamethoxazole-trimethoprim oral suspension and manufacture of oral dexamethasone are in...

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering. A total of 1,500,000 shares of its common stock were sold at a public offering price of $50.00 per share. The gross proceeds of the offerin...

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI” or the "Company") today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are ex...

ANI Pharmaceuticals (NASDAQ:ANIP) trades 5% down after hours on announcing its intention to offer and sell shares in an underwritten public offering. Underwriters granted 30-day option to purchase up to an additional 15% of shares. Offer size, terms not yet disclosed. Net proce...